Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study

Objective To describe and compare demographic and clinical profile of patients newly initiated on aclidinium (ACL) or tiotropium (TIO) and identify factors associated with newly initiated ACL in real-life clinical practice during 2013 in Catalonia. Design We performed a population-based, retrospective, observational study with data obtained from the Information System for Research Development in Primary Care, a population database that contains information of 5.8 million inhabitants (more than 80% of the Catalan population). Patients over 40 years old, with a recorded diagnosis of COPD and newly initiated treatment with either ACL or TIO during the study period (January to December 2013), were selected. A descriptive analysis of demographic and clinical characteristics was performed, and treatment adherence was also assessed for both cohorts. Results A total of 8,863 individuals were identified, 4,293 initiated with ACL and 4,570 with TIO. They had a mean age of 69.4 years (standard deviation: 11.3), a median COPD duration of 3 years (interquartile range: 0–8), and 71% were males. Patients treated with ACL were older, with more respiratory comorbidities, a longer time since COPD diagnosis, worse forced expiratory volume in 1 second (% predicted), and with a higher rate of exacerbations during the previous year compared with TIO. It was found that 41.3% of patients with ACL and 62.3% of patients with TIO had no previous COPD treatment. Inhaled corticosteroid and long-acting β2-agonist were the most frequent concomitant medications (32.9% and 32.6%, respectively). Approximately 75% of patients were persistent with ACL or TIO at 3 months from the beginning of treatment, and more than 50% of patients remained persistent at 9 months. Conclusion Patients initiated with ACL had more severe COPD and were taking more concomitant respiratory medications than patients initiated with TIO. ACL was more frequently initiated as part of triple therapy, while TIO was more frequently initiated as monotherapy.

[1]  Antonio Anzueto,et al.  A new two-step algorithm for the treatment of COPD , 2017, European Respiratory Journal.

[2]  I. Pavord,et al.  First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis , 2016, npj Primary Care Respiratory Medicine.

[3]  M. Miravitlles,et al.  The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis , 2016, International journal of chronic obstructive pulmonary disease.

[4]  K. Koehorst-ter Huurne,et al.  Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related , 2016, International journal of chronic obstructive pulmonary disease.

[5]  M. Miravitlles,et al.  Prevalence and Perception of 24-h Symptom Patterns in Patients With Stable Chronic Obstructive Pulmonary Disease in Spain , 2016 .

[6]  N. Leidy,et al.  The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies , 2016, Respiratory Research.

[7]  R. de Marco,et al.  Incidence, Predictors, and Clinical Implications of Discontinuing Therapy with Inhaled Long-Acting Bronchodilators among Patients with Chronic Obstructive Pulmonary Disease , 2016, COPD.

[8]  J. Izquierdo,et al.  Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD , 2016, International journal of chronic obstructive pulmonary disease.

[9]  Carl Llor,et al.  Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. , 2016, Respiratory medicine.

[10]  A. Chuchalin,et al.  A review of national guidelines for management of COPD in Europe , 2016, European Respiratory Journal.

[11]  D. Price,et al.  The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK , 2015, International journal of chronic obstructive pulmonary disease.

[12]  M. Miravitlles,et al.  Interactive Monitoring Service and COPD: Is it Possible to Reduce Nonadherence? , 2015, COPD.

[13]  D. Caillaud,et al.  Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment , 2015, European Respiratory Journal.

[14]  P. Candoli,et al.  COPD: adherence to therapy , 2014, Multidisciplinary Respiratory Medicine.

[15]  Mike Thomas,et al.  Quality standards for real-world research. Focus on observational database studies of comparative effectiveness. , 2014, Annals of the American Thoracic Society.

[16]  M. Decramer,et al.  Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. , 2013, The Lancet. Respiratory medicine.

[17]  C. Caracta,et al.  Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib Study , 2013, COPD.

[18]  A. Corrado,et al.  How far is real life from COPD therapy guidelines? An Italian observational study. , 2012, Respiratory medicine.

[19]  E. Bateman,et al.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study , 2012, European Respiratory Journal.

[20]  H. Magnussen,et al.  Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. , 2012, Chest.

[21]  K. Rabe,et al.  Tiotropium versus salmeterol for the prevention of exacerbations of COPD. , 2011, The New England journal of medicine.

[22]  A. Anzueto,et al.  Efficacy of tiotropium in the prevention of exacerbations of COPD , 2009, Therapeutic advances in respiratory disease.

[23]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[24]  J. Bourbeau,et al.  Patient adherence in COPD , 2008, Thorax.

[25]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary. , 2001, Respiratory care.

[26]  M. Artés,et al.  Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice. EOLO Group. Estudio Observacional de la Limitación Obstructiva al Flujo aEreo. , 1999, Respiratory medicine.

[27]  J. Soriano,et al.  Spanish guideline for COPD (GesEPOC). Update 2014. , 2014, Archivos de bronconeumologia.

[28]  J. Soriano,et al.  Spanish Guideline for COPD (GesEPOC). Update 2014 , 2014 .

[29]  Daniel Prieto-Alhambra,et al.  [SIDIAP database: electronic clinical records in primary care as a source of information for epidemiologic research]. , 2012, Medicina clinica.

[30]  M. Miravitlles,et al.  Variability in the performing of spirometry and its consequences in the treatment of COPD in primary care. , 2011 .

[31]  J. Cramer,et al.  Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[32]  J. L. Izquierdo Alonso,et al.  [Factors affecting drug prescription in patients with stable COPD: results from a multicenter Spanish study (IDENTEPOC)]. , 2005, Archivos de bronconeumologia.